2003
This foundational study showed that Epithalon activates telomerase (the enzyme that rebuilds telomeres) in human fibroblast cells that normally don't have active telomerase. The cells actually grew telomeres longer—suggesting the possibility of extending cellular lifespan.
Khavinson VKh, Bondarev IE, Butyugov AA
2025
This recent study confirmed that Epithalon extends telomeres in normal human cells by increasing telomerase activity. Importantly, in normal cells the effect worked through safe telomerase pathways, while cancer cells used a different mechanism—suggesting Epithalon may be safe for healthy cells.
Al-Dulaimi S, Thomas R, Matta S, Roberts T
2025
This comprehensive review summarized 25 years of Epithalon research, confirming its effects on melatonin synthesis, telomerase activity, and multiple enzymes. It's one of the broadest-reaching peptides studied in longevity science.
Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł
2017
Researchers confirmed that the AEDG sequence (Epithalon's four amino acids) naturally exists in the pineal gland's polypeptide complex (a mix of small proteins). This showed Epithalon is not just a synthetic invention, but is based on a natural peptide your body already uses.
Khavinson VKh, Kopylov AT, Vaskovsky BV, et al.
2025
Epithalon restored impaired wound healing in cells damaged by high glucose (simulating diabetes). It worked by reducing oxidative stress (damage from reactive oxygen) and preventing harmful cell changes, showing its potential beyond just telomere effects.
Gatta M, Dovizio M, Milillo C, et al.
2003
Thymalin (from the thymus, an immune gland) and Epithalamin (from the pineal gland) peptide preparations were assessed in 266 elderly people over 6-8 years, with the preparations given during the first 2-3 years. Mortality (death rate) fell 2.0-2.1-fold (2.0-2.1 times) in the Thymalin group, 1.6-1.8-fold in the Epithalamin group, and 2.5-fold with both. A separate group given both annually for 6 years showed a 4.1-fold decrease (4.1 times fewer deaths) against control. This study used Epithalamin, the pineal gland extract, not the lab-made four-amino-acid peptide Epitalon.
Khavinson VKh, Morozov VG
2003
In aging CBA mice, long-term use of the pineal preparation epithalamin increased stromal precursor cells (early cells that support blood-cell making), CD4+ cells (a type of T cell) and Mac-1+ cells (a type of immune cell) in old bone marrow, improved the movement of T-cell precursors (young immune cells) from bone marrow to the thymus, and shifted T-cell populations in the thymus and spleen back toward the pattern seen in adult mice. The authors also reported that Epithalon increased thymic endocrine function (hormone output of the thymus). This is animal research, not human data.
Labunets IF, Butenko GM, Khavinson VKh, Magdich LV, Dragunova VA, Pishel' IN, Azarskova MV
2006
A 12-year randomised clinical study (patients randomly assigned to treatment or comparison) of epithalamine, the pineal gland peptide preparation, not the lab-made four-amino-acid peptide, in elderly patients with coronary disease (narrowed heart arteries) and accelerated cardiovascular aging. After 12 years the number of deaths in the epithalamine group was 28% lower than in the control group on the same basic therapy. Cardiovascular mortality was 2-fold lower (half as high), as was the rate of cardiovascular failure and respiratory disease.
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA
2011
A randomized comparative study in which 39 elderly coronary patients (patients with narrowed heart arteries) received six courses of epithalamin over three years in addition to basic therapy, with 40 controls on basic therapy alone, followed for 15 years. Treated patients showed slower cardiovascular aging, kept their physical endurance, had a normalized melatonin circadian rhythm (a normal daily melatonin cycle), and had significantly lower mortality (death rate). The published report gives results on effectiveness and does not list side effects (adverse events).
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA